MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol - PubMed (original) (raw)
. 2004 Jul 8;23(31):5301-15.
doi: 10.1038/sj.onc.1207692.
Affiliations
- PMID: 15241487
- DOI: 10.1038/sj.onc.1207692
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
Aaron M Domina et al. Oncogene. 2004.
Abstract
BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events - mediated through separate signaling processes and involving different target sites - in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-independent sites.
Similar articles
- Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance.
Deng X, Kornblau SM, Ruvolo PP, May WS Jr. Deng X, et al. J Natl Cancer Inst Monogr. 2001;(28):30-7. doi: 10.1093/oxfordjournals.jncimonographs.a024254. J Natl Cancer Inst Monogr. 2001. PMID: 11158204 Review. - Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
Sancho M, Leiva D, Lucendo E, Orzáez M. Sancho M, et al. FEBS J. 2022 Oct;289(20):6209-6234. doi: 10.1111/febs.16136. Epub 2021 Aug 2. FEBS J. 2022. PMID: 34310025 Free PMC article. Review.
Cited by
- Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.
Jenkins LJ, Luk IY, Fairlie WD, Lee EF, Palmieri M, Schoffer KL, Tan T, Ng I, Vukelic N, Tran S, Tse JWT, Nightingale R, Alam Z, Chionh F, Iatropoulos G, Ernst M, Afshar-Sterle S, Desai J, Gibbs P, Sieber OM, Dhillon AS, Tebbutt NC, Mariadason JM. Jenkins LJ, et al. Mol Cancer Ther. 2023 Jan 3;22(1):52-62. doi: 10.1158/1535-7163.MCT-22-0101. Mol Cancer Ther. 2023. PMID: 36343387 Free PMC article. - SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain.
Murthy S, Ryan AJ, Carter AB. Murthy S, et al. Biochem J. 2012 Jul 15;445(2):229-36. doi: 10.1042/BJ20120053. Biochem J. 2012. PMID: 22519702 Free PMC article. - Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.
Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Tantawy SI, et al. Clin Cancer Res. 2023 Jan 17;29(2):446-457. doi: 10.1158/1078-0432.CCR-22-2088. Clin Cancer Res. 2023. PMID: 36346691 Free PMC article. - Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1.
Thomas LW, Lam C, Clark RE, White MR, Spiller DG, Moots RJ, Edwards SW. Thomas LW, et al. PLoS One. 2012;7(9):e45088. doi: 10.1371/journal.pone.0045088. Epub 2012 Sep 14. PLoS One. 2012. PMID: 23024798 Free PMC article. - The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD. Holt SV, et al. Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16. Br J Cancer. 2012. PMID: 22343622 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous